Initial clinical trials testing the efficacy of so-called “checkpoint blockade” with single agents, such as CLTA-4, PD-1 or PD-L1 blocking antibodies have clearly demonstrated their potential to augment immune responses against a range of human cancers, but have also revealed a limited benefit of monotherapy for the majority of treated patients [29,41,42,61]. This evidence concerns the gene CD274 and cancer.